Menu
Patient Assistance Program Patient Assistance Program

FREE AURYXIA FOR ELIGIBLE PATIENTS WHO ARE UNABLE TO AFFORD THEIR COPAYS

With AkebiaCares, eligible uninsured and Medicare Part D patients can get AURYXIA free of charge

*If you have any questions about an application after it has been submitted to AkebiaCares, please call 855-686-8601.

PATIENT ASSISTANCE PROGRAM ELIGIBILITY

AkebiaCares provides AURYXIA free of charge to patients who meet certain eligibility requirements, including:

  • Uninsured or without prescription drug coverage
  • Medicare Part D patients who cannot afford out-of-pocket costs

Depending on which indication AURYXIA was prescribed for.

Do you have questions about eligibility? Contact an AkebiaCares Case Manager.

Certain qualified patients or patients with an income up to 400% of the Federal Poverty Level (FPL) may be eligible for additional assistance through AkebiaCares. If you're unsure about your patient's eligibility status, be sure to reach out to your AkebiaCares Case Manager for help at 855-686-8601.

INDICATIONS

AURYXIA® (ferric citrate) is indicated for:

  • The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis
  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS

The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)
  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information